Effects of rosiglitazone (a peroxysome proliferator-activated receptor γ agonist) on the blood pressure and aortic structure in metabolically programmed (perinatal low protein) rats

Hypertension Research

Volumn 31, Issue 5, 2008, Pages 965-975

  Torres, Thiago da Silva ^a   d'Oliveira Silva, Geraldo ^a   Aguila, Márcia Barbosa ^a   de Carvalho, Jorge José ^a   Mandarim de Lacerda, Carlos A ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Arterial remodeling; Chronic diseases; Hypertension; Insulin; Peroxysome proliferator activated receptor agonist

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA FLOW; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; FEMALE; FOOD COMPOSITION; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MORNING DOSAGE; NONHUMAN; PREGNANCY; PROGENY; PROTEIN EXPRESSION; PROTEIN INTAKE; PROTEIN RESTRICTION; RAT; SMOOTH MUSCLE FIBER; TENSILE STRENGTH; TUNICA MEDIA; WEIGHT REDUCTION;

ANIMALS; AORTA; BLOOD GLUCOSE; BLOOD PRESSURE; CARBOHYDRATE METABOLISM; DIET, PROTEIN-RESTRICTED; DISEASE MODELS, ANIMAL; ELASTICITY; FEMALE; HYPERTENSION; HYPERTROPHY; INSULIN; LEPTIN; MALE; NITRIC OXIDE SYNTHASE TYPE III; PPAR GAMMA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; THIAZOLIDINEDIONES; TUNICA MEDIA;

EID: 46049111845     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.965     Document Type: Article

References (50)

1. Gallou-Kabani C, Junien C: Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes 2005; 54: 1899-1906.
2. Zandi-Nejad K, Luyckx VA, Brenner BM: Adult hypertension and kidney disease: the role of fetal programming. Hypertension 2006; 47: 502-508.
3. Heywood WE, Mian N, Milla PJ, Lindley KJ: Programming of defective rat pancreatic beta-cell function in offspring from mothers fed a low-protein diet during gestation and the suckling periods. Clin Sci (Lond) 2004; 107: 37-45.
4. Bonora E: The metabolic syndrome and cardiovascular disease. Ann Med 2006; 38: 64-80.
5. Olivetti G, Melissari M, Marchetti G, Anversa P: Quantitative structural changes of the rat thoracic aorta in early spontaneous hypertension. Tissue composition, and hypertrophy and hyperplasia of smooth muscle cells. Circ Res 1982; 51: 19-26.
6. Safar ME, London GM, Asmar R, Frohlich ED: Recent advances on large arteries in hypertension. Hypertension 1998; 32: 156-161.
7. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P: Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005; 45: 432-437.
8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
9. Granberry MC, Fonseca VA: Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005; 5: 201-209.
10. Brunani A, Caumo A, Graci S, Castagna G, Viberti G, Liuzzi A: Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. Diabetes Obes Metab 2008; 10: 460-467.
11. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H: Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005; 70: 20-25.
12. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD: PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43: 661-666.
13. Reeves PG, Nielsen FH, Fahey GC Jr: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993; 123: 1939-1951.
14. Langley-Evans SC, Gardner DS, Jackson AA: Maternal protein restriction influences the programming of the rat hypothalamic-pituitary-adrenal axis. J Nutr 1996; 126: 1578-1585.
15. Quinn R: Comparing rat's to human's age: how old is my rat in people years? Nutrition 2005; 21: 775-777.
16. Fullmer HM, Lillie RD: A selective stain for elastic tissue (orcinol-new fuchsin). Stain Technol 1956; 31: 27-29.
17. Carallo C, Irace C, Pujia A, et al: Evaluation of common carotid hemodynamic forces. Relations with wall thickening. Hypertension 1999; 34: 217-221.
18. Mandarim-de-Lacerda CA: Stereological tools in biomedical research. An Acad Bras Cienc 2003; 75: 469-486.
19. Pires KMP, Aguila MB, Mandarim-de-Lacerda CA: Early renal structure alteration in rat offspring from dams fed low protein diet. Life Sci 2006; 79: 2128-2134.
20. Ozanne SE: Metabolic programming in animals. Br Med Bull 2001; 60: 143-152.
21. Souza-Mello V, Mandarim-de-Lacerda CA, Aguila MB: Hepatic structural alteration in adult programmed offspring (severe maternal protein restriction) is aggravated by post-weaning high-fat diet. Br J Nutr 2007; 98: 1159-1169.
22. Brawley L, Itoh S, Torrens C, et al: Dietary protein restriction in pregnancy induces hypertension and vascular defects in rat male offspring. Pediatr Res 2003; 54: 83-90.
23. Langley-Evans SC: Intrauterine programming of hypertension in the rat: nutrient interactions. Comp Biochem Physiol A Physiol 1996; 114: 327-333.
24. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
25. Home PD, Pocock SJ, Beck-Nielsen H, et al: Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38.
26. Krall RL: Cardiovascular safety of rosiglitazone. Lancet 2007; 369: 1995-1996.
27. Yue TL, Bao W, Gu JL, et al: Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005; 54: 554-562.
28. Molavi B, Chen J, Mchta JL: Cardioprotective effects of rosiglitazone are associated with selective over-expression of type 2 angiotensin receptors and inhibition of P42/44 MAPK. Am J Physiol Heart Circ Physiol 2006; 291: H687-H693.
29. Gonon AT, Bulhak A, Labruto F, Sjoquist PO, Pernow J: Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 2007; 102: 80-89.
30. Bezie Y, Lacolley P, Laurent S, Gabella G: Connection of smooth muscle cells to elastic lamellae in aorta of spontaneously hypertensive rats. Hypertension 1998; 32: 166-169.
31. Skilton MR, Gosby AK, Wu BJ, et al: Maternal undernutrition reduces aortic wall thickness and elastin content in offspring rats without altering endothelial function. Clin Sci (Lond) 2006; 111: 281-287.
32. Giummelly P, Lartaud-Idjouadiene I, Marque V, et al: Effects of aging and antihypertensive treatment on aortic internal diameter in spontaneously hypertensive rats. Hypertension 1999; 34: 207-211.
33. Van Vre EA, van Beusekom HM, Vrints CJ, Bosmans JM, Bult H, Van der Giessen WJ: Stereology: a simplified and more time-efficient method than planimetry for the quantitative analysis of vascular structures in different models of intimal thickening, Cardiovasc Pathol 2007; 16: 43-50.
34. Woods LL, Ingelfinger JR, Nyengaard JR, Rasch R: Maternal protein restriction suppresses the newborn renin-angiotensin system and programs adult hypertension in rats. Pediatr Res 2001; 49: 460-467.
35. Yzydorezyk C, Gobeil F Jr, Cambonie G, et al: Exaggerated vasomotor response to ANG II in rats with fetal programming of hypertension associated with exposure to a low-protein diet during gestation. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1060-R1068.
36. Benkirane K, Viel EC, Amiri F, Schiffrin EL: Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006; 47: 102-108.
37. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL: PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol 2006; 290: H390-H397.
38. Molavi B, Chen J, Mehta JL: Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol 2006; 291: H687-H693.
39. Erbe DV, Gartrell K, Zhang YL, et al: Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006; 45: 154-162.
40. Harte A, McTernan P, Chetty R, et al: Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005; 111: 1954-1961.
41. Zhou MS, Schulman IH, Raij L: Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004; 24: 366-378.
42. Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M: Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol 2005; 38: 163-174.
43. do Carmo Pinho Franco M, Nigro D, Fortes ZB, et al: Intrauterine undernutrition - renal and vascular origin of hypertension. Cardiovasc Res 2003; 60: 228-234.
44. Franco Mdo C, Arruda RM, Dantas AP, et al: Intrauterine undernutrition: expression and activity of the endothelial nitric oxide synthase in male and female adult offspring. Cardiovasc Res 2002; 56: 145-153.
45. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM: Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25: 1810-1816.
46. De Ciuceis C, Amiri F, Iglarz M, Cohn JS, Touyz RM, Schiffrin EL: Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. Br J Pharmacol 2007; 151: 45-53.
47. Wang S, Jiang JL, Hu CP, Zhang XJ, Yang DL, Li YJ: Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells. Diabetes Metab Res Rev 2007; 23: 157-164.
48. Diep QN, El Mabrouk M, Cohn JS, et al: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-2302.
49. Iglarz M, Touyz RM, Viel EC, et al: Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003; 42: 737-743.
50. Gao DF, Niu XL, Hao GH, et al: Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol 2007; 73: 185-197.